Novocure’s response to COVID-19
Important information for our patients, caregivers and providers
Learn More
focusing on
the details
Dario Garcia-Carracedo sees how his work as Associate Director of Medical Affairs fits into the big picture at Novocure.
MORE
unafraid
to innovate
Katia Felix, Associate Director of Global Strategic Development, moved into a new role created for her after sharing an idea that could positively impact the company.
MORE
Medicare
update
The Medicare Durable Medical Equipment Medicare Administrative Contractors have released a final local coverage determination providing coverage of Novocure’s cancer treatment for Medicare beneficiaries with newly diagnosed glioblastoma.
Learn More
FDA approves Novocure’s cancer treatment for MPM
The U.S. FDA has approved Tumor Treating Fields for the treatment of unresectable malignant pleural mesothelioma.
LEARN MORE
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with nearly 600 employees and operations in the U.S., Europe and Asia.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD